tbc-11251 has been researched along with Cardiovascular Diseases in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Biswal, S | 1 |
| Blackwell, S; Dhaun, N; Goddard, J; Johnston, NR; Melville, V; Talwar, DK; Webb, DJ | 1 |
| McLaughlin, VV; Rich, S | 1 |
1 review(s) available for tbc-11251 and Cardiovascular Diseases
| Article | Year |
|---|---|
Endothelin receptor blockers in cardiovascular disease.
Topics: Animals; Antihypertensive Agents; Bosentan; Cardiovascular Diseases; Endothelin Receptor Antagonists; Exercise Tolerance; Hemodynamics; Humans; Isoxazoles; Sulfonamides; Thiophenes | 2003 |
1 trial(s) available for tbc-11251 and Cardiovascular Diseases
| Article | Year |
|---|---|
Endothelin-A receptor antagonism modifies cardiovascular risk factors in CKD.
Topics: Adult; Biomarkers; Blood Pressure; Cardiovascular Diseases; Cross-Over Studies; Double-Blind Method; Endothelin Receptor Antagonists; Endothelin-1; Female; Humans; Isoxazoles; Male; Middle Aged; Nifedipine; Proteinuria; Pulse Wave Analysis; Renal Insufficiency, Chronic; Thiophenes; Vascular Stiffness; Vasodilator Agents | 2013 |
1 other study(ies) available for tbc-11251 and Cardiovascular Diseases
| Article | Year |
|---|---|
Novel cardiovascular drugs in clinical trials.
Topics: Anticholesteremic Agents; Benzaldehydes; Cardiovascular Agents; Cardiovascular Diseases; Clinical Trials as Topic; Endothelin Receptor Antagonists; Fibrinolytic Agents; Humans; Immunologic Factors; Isoxazoles; Lipoxygenase Inhibitors; Metalloendopeptidases; Oxazolidinones; Oximes; Phospholipase A2 Inhibitors; Probucol; Pyrimidines; Quinolines; Thiophenes | 2010 |